Bavarian Nordic A/S (CPH:BAVA)
Denmark · Delayed Price · Currency is DKK | Market Cap | 18.39B |
| Revenue (ttm) | 6.46B |
| Net Income (ttm) | 1.42B |
| Shares Out | 78.24M |
| EPS (ttm) | 17.97 |
| PE Ratio | 13.08 |
| Forward PE | 14.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 159,971 |
| Average Volume | 439,722 |
| Open | 236.00 |
| Previous Close | 235.10 |
| Day's Range | 236.00 - 238.40 |
| 52-Week Range | 123.30 - 244.80 |
| Beta | 1.10 |
| RSI | 50.72 |
| Earnings Date | Nov 14, 2025 |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite... [Read more]
Financial Performance
In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.
Financial StatementsNews
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
COPENHAGEN, Denmark, November 4, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley th...
Bavarian Nordic Provides Clarification on the HERA Framework Agreement and the Public Preparedness Business
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and Response Authority (HERA) framework agreement, ann...
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley th...
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Bavarian Nordic signs EU smallpox and mpox vaccine contract for up to 8 million doses
Bavarian Nordic announced on Friday a new contract with the European Commission, allowing countries across Europe to buy up to eight million doses of its smallpox and mpox vaccine over the next four y...
Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox
COPENHAGEN, Denmark, October 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the award of a joint procurement contract by the European Commission, through the Health Emergency Preparedness ...
Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines
COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa.
Consortium consisting of Nordic Capital and Permira lowers the minimum acceptance condition to 66 2/3% in respect of the takeover offer to the shareholders of Bavarian Nordic
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Bavarian Nordic's Largest Shareholder Stands Firm Against $3.1 Billion Private-Equity Takeover Bid
ATP's rejection of a sweetened bid from private-equity firms for the vaccine maker casts doubt over whether the deal will go through.
The Board of Directors maintains its recommendation in supplementary statement in respect of the improved takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Bavarian Nordic (BVNRY) Secures Higher Buyout Offer
Bavarian Nordic (BVNRY) Secures Higher Buyout Offer
Bavarian Nordic draws higher bid for take-private deal
Bavarian Nordic (BVNRY) stock is in focus as the company receives an increased takeover bid from Nordic Capital & Permira. Read more here.
Nordic Capital-led consortium raises takeover price for Bavarian Nordic to $38.94 per share
Bavarian Nordic said on Wednesday a consortium led by Nordic Capital and Permira has raised its offer price for the vaccine maker to 250 Danish crowns ($38.94) after its initial bid was not accepted b...
Consortium consisting of Nordic Capital and Permira increases offer price and extends offer period until 5 November 2025 in respect of the takeover offer to the shareholders of Bavarian Nordic
COPENHAGEN, Denmark, October 15, 2025 – With reference to the announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document (the "Offer Document") concerning the all-cas...
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Consortium consisting of Nordic Capital and Permira receives final regulatory approval in respect of its takeover offer to the shareholders of Bavarian Nordic
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Bavarian Nordic Reports Positive Topline Data for Mpox/Smallpox Vaccine in Pediatric Population
COPENHAGEN, Denmark, October 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) today reported topline results from a clinical study of its MVA-BN® mpox/smallpox vaccine in children 2 to 11 years of age.
Consortium consisting of Nordic Capital and Permira extends offer period until 14 October 2025 and provides update on regulatory approvals in respect of the takeover offer to the shareholders of Bavarian Nordic
COPENHAGEN, Denmark, September 29, 2025 – With reference to the announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document (the "Offer Document") concerning the all-c...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, September 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 3,818,710 as a consequence of employees' e...
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75%
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Bavarian Nordic AS (BVNKF) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Bavarian Nordic AS (BVNKF) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Market Expansions
Bavarian Nordic A/S 2025 Q2 - Results - Earnings Call Presentation
Bavarian Nordic A/S (BVNKF) Q2 2025 Earnings Call Transcript
Bavarian Nordic beats revenue expectations, as launch of takeover bid nears
Bavarian Nordic , subject of a takeover offer valuing the vaccine maker at about 19 billion Danish crowns ($3 billion), reported a higher than expected revenue for the second quarter on Friday, citing...